Friday, October 14, 2011
Celiac Disease Phase 2a Trial With ALV003, Positive Results
According to an announcement made today by Alvine Pharmaceuticals, Inc., the Phase 2a clinical trial of ALV003 produced positive results, demonstrating its ability to attenuate gluten-induced intestinal mucosal injury in serologically negative celiac disease patients maintained on a gluten-free diet for one or more years. The results of the study will be presented on October 24 at the 19th United European Gastroenterology (UEGW) in Stockholm in the late breaking news. The full report (#OP050B) can currently be viewed on the UEGW website at www.uegw11.uegf.org. Peter Green, M.D...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment